Importer of Controlled Substances: Notice of Application, 21998 [2012-8761]
Download as PDF
<![CDATA[
21998
Federal Register / Vol. 77, No. 71 / Thursday, April 12, 2012 / Notices
Square, 145 N Street NE., Room 2E–508,
Washington, DC 20530.
Jerri Murray,
Department Clearance Officer, PRA, U.S.
Department of Justice.
[FR Doc. 2012–8398 Filed 4–11–12; 8:45 am]
BILLING CODE 4410–12–P
Dated: April 2, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on DSK4VPTVN1PROD with NOTICES
Importer of Controlled Substances:
Notice of Application
[FR Doc. 2012–8761 Filed 4–11–12; 8:45 am]
BILLING CODE 4410–09–P
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on
December 7, 2011, Meda
Pharmaceuticals Inc., 705 Eldorado
Street, Decatur, Illinois 62523, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of Nabilone
(7379), a basic class of controlled
substance listed in schedule II.
The company plans to import the
listed controlled substance for
distribution to its customers.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration,
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21
CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than May 14, 2012.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance listed in
schedule I or II are, and will continue
VerDate Mar<15>2010
16:27 Apr 11, 2012
Jkt 226001
to be, required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances,
Notice of Application, Lipomed, Inc.
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on January
30, 2012, Lipomed, Inc., One Broadway,
Cambridge, Massachusetts 02142, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the
following basic classes of controlled
substances:
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
4-methyl-N-methylcathinone
(1248).
N–Ethylamphetamine (1475) ........
N,N–Dimethylamphetamine
(1480).
Fenethylline (1503) .......................
Aminorex (1585) ...........................
4–Methylaminorex (cis isomer)
(1590).
Gamma
Hydroxybutyric
Acid
(2010).
Methaqualone (2565) ...................
Mecloqualone (2572) ....................
1–Pentyl-3-(1-naphthoyl)indole
(7118).
1–Butyl-3-(1-naphthoyl)-indole
(7173).
1-[2-(4–Morpholinyl)ethyl]-3–1(1naphthoyl) indole (7200).
Alpha-ethyltryptamine (7249) .......
Ibogaine (7260) ............................
5-(1,1–Dimethylheptyl)-2-[(1R,3S)3-
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Drug
hydroxycyclohexyl]-phenol (7297)
5-(1,1–Dimethyloctyl)-2-[(1R,3S)3hydroxycyclohexyl]-phenol (7298)
Lysergic acid diethylamide (7315)
2,5–Dimethoxy-4-(n)propylthiophenethylamine
(7348).
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Parahexyl (7374) ..........................
Nabilone (7379) ............................
Mescaline (7381) ..........................
3,4,5–Trimethoxyamphetamine
(7390).
4–Bromo-2,5dimethoxyamphetamine (7391).
4–Bromo-2,5dimethoxyphenethylamine
(7392).
4–Methyl-2,5dimethoxyamphetamine (7395).
2,5–Dimethoxyamphetamine
(7396).
2,5–Dimethoxy-4ethylamphetamine (7399).
3,4–Methylenedioxyamphetamine
(7400).
5–Methoxy-3,4methylenedioxyamphetamine
(7401).
N–Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4–Methylenedioxy-Nethylamphetamine (7404).
3,4–
Methylenedioxymethamphetamine (7405).
4–Methoxyamphetamine (7411) ...
5–Methoxy-N–Ndimethyltryptamine (7431).
Alpha-methyltryptamine (7432) ....
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
5–Methoxy-N,Ndiisopropyltryptamine (7439).
N–Ethyl-1-phenylcyclohexylamine
(7455).
1-(1–Phenylcyclohexyl)pyrrolidine
(7458).
1-[1-(2–
Thienyl)cyclohexyl]piperidine
(7470).
1-[1-(2–
Thienyl)cyclohexyl]pyrrolidine
(7473).
N–Ethyl-3-piperidyl
benzilate
(7482).
N–Methyl-3-piperidyl
benzilate
(7484).
N–Benzylpiperazine (7493) ..........
3,4-methylenedioxypyrovalerone
(7535).
3,4-methylenedioxy-Nmethylcathinone (7540).
Alphaprodine (9010) .....................
Acetyldihydrocodeine (9051) ........
Benzylmorphine (9052) ................
Codeine-N-oxide (9053) ...............
Cyprenorphine (9054) ..................
Desomorphine (9055) ...................
Etorphine (except HCl) (9056) .....
E:\FR\FM\12APN1.SGM
12APN1
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
]]>Agencies
[Federal Register Volume 77, Number 71 (Thursday, April 12, 2012)]
[Notices]
[Page 21998]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-8761]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances: Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on December 7, 2011, Meda Pharmaceuticals Inc., 705 Eldorado
Street, Decatur, Illinois 62523, made application by renewal to the
Drug Enforcement Administration (DEA) to be registered as an importer
of Nabilone (7379), a basic class of controlled substance listed in
schedule II.
The company plans to import the listed controlled substance for
distribution to its customers.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration, and may, at the same time, file a written
request for a hearing on such application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21 CFR 1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than May 14, 2012.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic class of any controlled substance
listed in schedule I or II are, and will continue to be, required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: April 2, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-8761 Filed 4-11-12; 8:45 am]
BILLING CODE 4410-09-P
